-
公开(公告)号：EP2059248A1
公开(公告)日：2009-05-20
申请号：EP08707797.0
申请日：2008-02-23
IPC分类号： A61K31/57 , A61K31/573 , A61P15/00
CPC分类号： A61K31/57 , A61K31/573
摘要： A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17α-cyanomethyl-17ß-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetate or chlormadinonacetate at a daily dosage which is no more than two times the dosage required to suppress ovulation, together with one or a plurality of pharmaceutically acceptable adjuvants/carriers. The pharmaceutical composition according to the invention provides both the alleviation of endometriosis and the lack of a negative affect on bone metabolism and bone density, and is simultaneously able to keep the side effects known from conventional pharmaceuticals (such as hot flashes, acne, negative affects on the lipid profile) within tolerable limits. The pharmaceutical composition is thus suitable for long-term application.
-
2.发明授权2-(3-PHENYL-2-PIPERAZINYL-3,4-DIHYDROCHINAZOLIN-4-YL) ESSIGSÄUREN ALS ANTIVIRALE MITTEL, SPEZIELL GEGEN CYTOMEGALIEVIREN 有权2-（3-苯基-2-哌嗪基-3,4-二氢喹唑啉-4-基）乙酸可用作抗病毒剂，特别是在巨细胞病毒
公开(公告)号：EP1603888B1
公开(公告)日：2011-01-12
申请号：EP04706148.6
申请日：2004-01-29
发明人： WUNBERG, Tobias , BAUMEISTER, Judith , BETZ, Ulrich , JESKE, Mario , KLEYMANN, Gerald , LAMPE, Thomas , NIKOLIC, Susanne , REEFSCHLÄGER, Jürgen , SCHOHE-LOOP, Rudolf , SÜßMEIER, Frank , ZIMMERMANN, Holger , GROSSER, Rolf , HENNINGER, Kerstin , HEWLETT, Guy , KELDENICH, Jörg , KRÄMER, Thomas , NELL, Peter , LIN, Tse-I
IPC分类号： C07D239/84 , A61K31/517 , A61P31/22
CPC分类号： C07D239/84
摘要： The invention relates to dihydroquinazolines and methods for the production thereof, the use thereof in the treatment and/or prophylaxis of diseases, in addition to the use thereof in the production of medicaments in the treatment and/or prophylaxis of diseases, especially for use as anti-viral agents, especially against cytomegalo viruses.
-
3.发明公开VERWENDUNG VON ESTRADIOLVALERAT ODER 17ß-ESTRADIOL IN KOMBINATION MIT DIENOGEST ZUR ORALEN THERAPIE FÜR DEN ERHALT UND/ODER STEIGERUNG DER WEIBLICHEN LIBIDO 审中-公开17雌二醇或戊酸雌二醇联合使用诺孕素口服治疗获得和/或增加女性性欲
公开(公告)号：EP2083827A1
公开(公告)日：2009-08-05
申请号：EP07818937.0
申请日：2007-10-12
发明人： ZEUN, Susan , ZIMMERMANN, Holger , PARKE, Susanne
IPC分类号： A61K31/565 , A61K31/57 , A61P15/12 , A61P15/18 , A61P15/00
CPC分类号： A61K31/565 , A61K31/57 , A61K2300/00
摘要： The invention relates to the use of estradiol valerate or estradiol in combination with 17a-cyanomethyl-17-β-hydroxyestra-4,9-dien-3-one (dienogest) in a multiphase or single-phase combination preparation for oral therapy for maintaining and/or increasing the female libido, optionally also in unity with oral contraception. The total daily dose units of the multiphase combination and of the pharmaceutically acceptable placebo or of the single-phase combination and the active-ingredient-free and placebo-free daily dose units correspond to 28 days.
-
4.发明公开VERWENDUNG VON GESTAGENEN IN KOMBINATION MIT (6S)5-METHYLTETRAHYDROFOLAT ZUR THERAPIE DER ENDOMETRIOSE MIT GLEICHZEITIGER VERMINDERUNG VON THERAPIE-NEBENWIRKUNGEN SOWIE DER VERMINDERUNG DES RISIKOS ANGEBORENER FEHLBILDUNGEN BEI EINTRITT EINER GRAVIDITÄT 审中-公开孕激素的IN与还原剂先天性畸形的危险妊娠入院治疗和副作用同时减少子宫内膜异位症（6S）-5-甲基四氢叶酸联合治疗中使用
公开(公告)号：EP2194978A1
公开(公告)日：2010-06-16
申请号：EP08785200.0
申请日：2008-07-30
发明人： SEITZ, Christian , WASSERFALL, Annemarie , DIEFENBACH, Konstanze , KING, Kristina , ZIMMERMANN, Holger
IPC分类号： A61K31/195 , A61K31/495 , A61K31/505 , A61K31/519 , A61K31/565 , A61K31/57 , A61P15/02 , A61P15/12 , A61P15/18 , A61P19/10 , A61P43/00
CPC分类号： A61K45/06 , A61K31/195 , A61K31/495 , A61K31/505 , A61K31/519 , A61K31/565 , A61K31/57 , A61K2300/00
摘要： Antiandrogenic gestagens in a daily dosage unit, corresponding to no more than two times the dosage required to suppress ovulation, are used in combination with (6S)-5-methyltetrahydrofolate for the production of pharmaceutical preparations for the therapy of endometrioses with simultaneous reduction of therapy side effects, such as the negative impact on bone density/bone metabolism and the risk for osteoporosis, and in the event of pregnancy, the reduction of the risk on congenital malformations, such as neural tube defects, cheilognathopalatoschisis and complications during pregnancy, such as the detachment of the placenta and premature birth. The invention is suitable for long-term use.
-
5.发明授权VERWENDUNG VON ESTRADIOLVALERAT ODER ESTRADIOL IN KOMBINATION MIT DIENOGEST ZUR ORALEN THERAPIE DER DYSFUNKTIONELLEN UTERINEN BLUTUNG IN EINHEIT MIT EINER ORALEN KONTRAZEPTION 有权使用或雌激素雌二醇结合诺孕素FOR出血的功能失调性子宫出血单元口服避孕药口服治疗
公开(公告)号：EP1933843B1
公开(公告)日：2011-02-02
申请号：EP06806225.6
申请日：2006-10-12
发明人： ZEUN, Susan , BOUDES, Pol , ENDRIKAT, Jan , SECCI, Angelo , ZIMMERMANN, Holger
IPC分类号： A61K31/565 , A61K31/57 , A61P15/00 , A61P15/18
CPC分类号： A61K31/565 , A61K31/57 , A61K2300/00
摘要： The invention relates to the use of estradiol valerate or estradiol combined with 17a- cyanomethyl-17-ß-hydroxyestra-4,9-diene-3on (dienogest) for producing a multi-phase combination preparation for the oral therapy of the dysfunctional uterine bleeding in the form of oral contraceptives. Said combination of estradiol valerate or estradiol with dienogest comprises a first phase consisting of 2 daily dose units of estradiol valerate at 3 mg or estradiol of less than 3mg, a second phase consisting of 2 groups of daily dose units, whereby the first group contains 5 daily dose units of a combination of 2 mg estradiol valerate or estradiol of less than 2mg and 2 mg of dienogest and the second group contains 17 daily dose units consisting of a combination of 2 mg of estradiol valerate or estradiol of less than 2mg and 3 mg dienogest, a third phase consisting of 2 daily dose units having 1 mg estradiol valerate or estradiol of less than 2mg and an additional phase consisting of 2 daily dose units on a pharmaceutically harmless placebo. All of the daily dose units of the multi-phase combination and the pharmaceutically harmless placebo correspond to 28 days. The duration of application comprises at least one menstruation cycle and is dependent on individual wishes of the woman with respect to contraception.
-
6.发明公开VERWENDUNG VON ESTRADIOLVALERAT ODER ESTRADIOL IN KOMBINATION MIT DIENOGEST ZUR ORALEN THERAPIE DER DYSFUNKTIONELLEN UTERINEN BLUTUNG IN EINHEIT MIT EINER ORALEN KONTRAZEPTION 有权使用或雌激素雌二醇结合诺孕素FOR出血的功能失调性子宫出血单元口服避孕药口服治疗
公开(公告)号：EP1933843A1
公开(公告)日：2008-06-25
申请号：EP06806225.6
申请日：2006-10-12
发明人： ZEUN, Susan , BOUDES, Pol , ENDRIKAT, Jan , SECCI, Angelo , ZIMMERMANN, Holger
IPC分类号： A61K31/565 , A61K31/57 , A61P15/00 , A61P15/18
CPC分类号： A61K31/565 , A61K31/57 , A61K2300/00
摘要： The invention relates to the use of estradiol valerate or estradiol combined with 17a- cyanomethyl-17-ß-hydroxyestra-4,9-diene-3on (dienogest) for producing a multi-phase combination preparation for the oral therapy of the dysfunctional uterine bleeding in the form of oral contraceptives. Said combination of estradiol valerate or estradiol with dienogest comprises a first phase consisting of 2 daily dose units of estradiol valerate at 3 mg or estradiol of less than 3mg, a second phase consisting of 2 groups of daily dose units, whereby the first group contains 5 daily dose units of a combination of 2 mg estradiol valerate or estradiol of less than 2mg and 2 mg of dienogest and the second group contains 17 daily dose units consisting of a combination of 2 mg of estradiol valerate or estradiol of less than 2mg and 3 mg dienogest, a third phase consisting of 2 daily dose units having 1 mg estradiol valerate or estradiol of less than 2mg and an additional phase consisting of 2 daily dose units on a pharmaceutically harmless placebo. All of the daily dose units of the multi-phase combination and the pharmaceutically harmless placebo correspond to 28 days. The duration of application comprises at least one menstruation cycle and is dependent on individual wishes of the woman with respect to contraception.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.011 秒)
